2,952 Shares in Johnson & Johnson $JNJ Acquired by Pacific Excel Wealth Advisors Inc.

Pacific Excel Wealth Advisors Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,952 shares of the company’s stock, valued at approximately $750,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Auto Owners Insurance Co lifted its position in Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Norges Bank bought a new position in Johnson & Johnson during the 4th quarter worth about $6,924,523,000. Capital World Investors acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $2,005,942,000. Diamant Asset Management Inc. lifted its holdings in shares of Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after purchasing an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after buying an additional 3,731,074 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $255.26 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a 50 day moving average price of $246.74 and a 200 day moving average price of $239.05. The stock has a market capitalization of $615.15 billion, a PE ratio of 29.58, a price-to-earnings-growth ratio of 2.41 and a beta of 0.24. Johnson & Johnson has a 52 week low of $169.65 and a 52 week high of $274.90.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the prior year, the business posted $2.77 EPS. The business’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts predict that Johnson & Johnson will post 11.69 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is currently 62.11%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA authorization opens a new growth avenue: The FDA authorized J&J’s OTTAVA robotic surgical system, marking the company’s entry into surgical robotics. Investors view the platform as a potentially meaningful long-term growth driver and a way to diversify beyond pharmaceuticals and medical devices. Johnson & Johnson Gets FDA Nod for OTTAVA
• Positive Sentiment: Strong oncology performance supports earnings growth: Darzalex, Erleada and newer cancer treatments drove solid second-quarter oncology growth, reinforcing expectations that Innovative Medicine can offset pressure from products facing patent expirations. J&J recently exceeded quarterly EPS and revenue estimates and reaffirmed fiscal 2026 EPS guidance of $11.60-$11.75. J&J’s Strong Q2 Oncology Performance Fuels Future Growth Hopes
• Positive Sentiment: Higher analyst valuation: Wells Fargo raised its JNJ price target from $272 to $282 and maintained an Overweight rating, suggesting further upside based on the company’s earnings outlook and growth initiatives. Wells Fargo price-target report
• Neutral Sentiment: Leadership transition announced: Innovative Medicine chairman Jennifer Taubert will retire after more than 21 years with J&J. Tom Cavanaugh will succeed her as executive vice president and worldwide chairman in September. Taubert oversaw the division’s expansion to more than $60 billion in annual revenue, while the transition creates some execution uncertainty. Johnson & Johnson leadership change
• Neutral Sentiment: Competitive concerns appear limited: An analyst covering Intuitive Surgical characterized OTTAVA as a potential growth catalyst rather than a major competitive threat, reducing concerns that J&J’s entry will immediately disrupt the established robotics market. Analyst commentary on OTTAVA

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

JNJ has been the subject of a number of research reports. Scotiabank reiterated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Citigroup boosted their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $267.48.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.